Lancet: Aspirin May Reduce Colon Cancer Risk in People With Lynch Syndrome

Lynch syndrome is associated with an increased risk of many tumors, especially endometrial cancerIn 2011, researchers examined the long-term effects of daily aspirin use on tumorpreventionin people with Lynch syndrome, and after an average follow-up of 55.7 months, researchers recently published a long-term assessment of regular aspirin useCAPP2 trial, 861 people with Lynch syndrome from 43 centres worldwide (707 in Europe, 82 per cent; 112 in Australia, 13 per cent; 38 in Africa, 4 per cent; and 4 in the Americas, 1 per cent) were randomly taken daily with 600 mg of aspirin or a placeboThe main endpoint iscolorectal cancerdiagnosed861 Lynch syndrome patients with an average age of 45 were involved in the study, of which 427 (50%) of participants received aspirin and 434 (50%) received placebo treatmentThe average follow-up was 10 years, about 8,500 people-yearsForty (9%) of the 427 subjects who took aspirin developed colorectal cancer, while 58 (13%) of the 434 placebo subjects developed colorectal cancerCox proportional risk analysis showed a significant lying risk of aspirin compared to placebo (0.65) and a negative two regression analyses showed a reduced risk (0.58)An analysis of 509 participants who received two years of intervention showed an HR of 0.56 and a incidence rate of 0.50The difference in the rate of adverse events between groups was not significantresearch supported, people with Lynch syndrome take aspirin to prevent colorectal cancer